Lyka Labs Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 23, 2026
- Posted by: Kunal Singla
- Category: News
The Lyka Labs share price target 2026 is Rs 81.9, implying approximately 20 percent upside from the current market price of Rs 68.27 (NSE: LYKALABS). With Q4 FY26 results released in 2026 and Injectable Pharmaceuticals and Formulations tailwinds in focus, the Rs 81.9 price objective is supported by the FY27 earnings recovery thesis.
Lyka Labs (NSE: LYKALABS) is a Injectable Pharmaceuticals and Formulations company trading at Rs 68.27 with a market capitalisation of Rs 273 crore. Analysts have set the Lyka Labs share price target at Rs 81.9 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Lyka Labs Share Price Target 2026: Key Takeaways
- Lyka Labs share price target 2026: Rs 81.9 (20% upside from CMP Rs 68.27)
- Bull case: Rs 99 | Bear case: Rs 54.6
- Ticker: LYKALABS | Sector: Injectable Pharmaceuticals and Formulations | MCap: Rs 273 crore
- 52W range: Rs 47 to Rs 112 | PE: 15x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Lyka Labs Company Overview
Lyka Labs (NSE: LYKALABS) is a Mumbai-based pharmaceutical company manufacturing injectable formulations, IV fluids, and branded generics for hospital supply and institutional distribution across India. At CMP Rs 68.27 against a 52 week range of Rs 47 to Rs 112, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 273 crore with trailing PE of 15x. Compared to peers in injectable pharma like Gland Pharma and Bharat Serums, Lyka Labs is positioned as a potential re-rating candidate toward the Rs 81.9 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | LYKALABS |
| Sector | Injectable Pharmaceuticals and Formulations |
| CMP (2026) | Rs 68.27 |
| 52 Week High | Rs 112 |
| 52 Week Low | Rs 47 |
| Market Cap | Rs 273 crore |
| Trailing PE | 15x |
| 12-Month Analyst Target | Rs 81.9 |
| Bull Case Target | Rs 99 |
| Bear Case Target | Rs 54.6 |
Why Is the Lyka Labs Share Price Target Set at Rs 81.9 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Lyka Labs share price target of Rs 81.9 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 81.9 price objective represents the base case with FY27 execution as the key variable.
Structural Sector Tailwinds in Injectable Pharmaceuticals and Formulations
The Injectable Pharmaceuticals and Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Lyka Labs’s position among peers in injectable pharma like Gland Pharma and Bharat Serums creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 99 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Lyka Labs’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 81.9 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Lyka Labs’s Injectable Pharmaceuticals and Formulations operations, improving the probability of achieving the Rs 81.9 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Lyka Labs is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 99 bull case over the medium term.
Lyka Labs Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Lyka Labs Share Price Target
Near-term support for Lyka Labs is anchored close to the 52 week low of Rs 47. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.
12-Month Lyka Labs Share Price Target 2026
The 12-month Lyka Labs share price target 2026 is Rs 81.9, implying approximately 20 percent upside from CMP Rs 68.27. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker LYKALABS.
Long Term Lyka Labs Share Price Target: FY27 to FY28
The long term Lyka Labs share price target for FY27 to FY28 is Rs 99 in the bull case, requiring full earnings delivery, re-rating among peers in injectable pharma like Gland Pharma and Bharat Serums, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Lyka Labs in 2026
Bull Case Lyka Labs Share Price Target: Rs 99
The bull case Lyka Labs share price target of Rs 99 materialises when FY27 earnings beat analyst estimates, Injectable Pharmaceuticals and Formulations tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 68.27, this represents approximately 45 percent potential upside.
Bear Case Lyka Labs Share Price Target: Rs 54.6
The bear case Lyka Labs share price target of Rs 54.6 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 47.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 99 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 81.9 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 54.6 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Lyka Labs 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Lyka Labs share price target of Rs 81.9, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 81.9 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Injectable Pharmaceuticals and Formulations Peers
Intensifying competition from peers in injectable pharma like Gland Pharma and Bharat Serums could compress Lyka Labs’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 81.9 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Lyka Labs
Check the Univest Screener for live data
Before considering any investment based on the Lyka Labs share price target of Rs 81.9, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Injectable Pharmaceuticals and Formulations sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Lyka Labs (NSE: LYKALABS) with regulatory protection. Study the competitive landscape among peers in injectable pharma like Gland Pharma and Bharat Serums before executing any position.
Plan your entry using the 52 week low of Rs 47 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 81.9 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Lyka Labs’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Lyka Labs Share Price Target 2026
What is the Lyka Labs share price target for 2026?
Ans. The Lyka Labs share price target 2026 is Rs 81.9, implying approximately 20 percent upside from CMP Rs 68.27. Bull case is Rs 99, bear case is Rs 54.6.
What was the Lyka Labs share price target for 2025?
Ans. The 2025 price objective for Lyka Labs was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 81.9, reflecting FY27 growth potential from CMP Rs 68.27.
Is Lyka Labs a good investment at Rs 68.27?
Ans. At Rs 68.27, Lyka Labs offers potential upside toward Rs 81.9 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Lyka Labs share price target 2026?
Ans. Key risks to the Lyka Labs share price target of Rs 81.9 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Injectable Pharmaceuticals and Formulations. Monitoring quarterly results is essential.
What is the 52 week high and low of Lyka Labs?
Ans. The 52 week high of Lyka Labs is Rs 112 and the 52 week low is Rs 47. At CMP Rs 68.27, the stock offers potential upside toward the Rs 81.9 price objective.
What are the main growth catalysts for Lyka Labs in 2026?
Ans. Key catalysts include FY27 PAT recovery, Injectable Pharmaceuticals and Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Lyka Labs compare to its peers?
Ans. Lyka Labs operates in Injectable Pharmaceuticals and Formulations alongside peers in injectable pharma like Gland Pharma and Bharat Serums. At CMP Rs 68.27 with MCap Rs 273 crore, it is a potential re-rating candidate toward the Lyka Labs share price target of Rs 81.9 on FY27 delivery.
What is the Lyka Labs share price target for 2027?
Ans. The long-term Lyka Labs share price target for FY27 to FY28 is Rs 99 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
